Nashwa Butler M.D.

[Nashwa Butler M.D. @ButlerNash81070]

@AshleyMPapa @FoxNews I spoke to congressman Brandon Gills today to pass on the company information to you. Hope it is helpful to you.

[Nashwa Butler M.D. @ButlerNash81070]

@realBrandonGill It was so nice talking to you today. You are definitely special.

[Nashwa Butler M.D. @ButlerNash81070]

Ashley contact Cytodyn
Leronlimab targets the CCR5 receptor. For appendix cancer, this could help by blocking CCR5 signaling, which is often upregulated and promotes metastasis and immune
suppression. A patent for a Phase two basket trial mentions appendix cancer as one of twenty-two solid tumor types included.
They have 5 mTNBC patients from that basket trial (compassionate use) that are still alive and disease free almost 6 years. The FDA has expanded access program for mTNBC ,but you may be able to get it right to try or compassionate use with the company and your doctor.
https://t.co/iCMQtmXg9t

[Nashwa Butler M.D. @ButlerNash81070]

@Cytodyn2026 https://t.co/7PrOlMeg2Y

[Leronlimab @Cytodyn2026]

https://t.co/fkXkmDNYeu

[Mike Sheikh @MikeSheikh2]

Part 3 $CYDY arguably some of the best mouse data in cancer. 98% reduction in 6 weeks.

[Mike Sheikh @MikeSheikh2]

Part 2 $CYDY

[Mike Sheikh @MikeSheikh2]

Part 1 $CYDY a metastatic #cancer company. #JPM26 #biotechshowcase

[Nashwa Butler M.D. @ButlerNash81070]

@MikeSheikh2 Leronlimab upregulates PD-L1, turning cold tumors hot. Since checkpoint inhibitors like Keytruda work mainly in PD-L1–positive patients (~15%), Leronlimab could make most solid tumor patients eligible. This represents a true paradigm shift in solid tumor treatment.

[Nashwa Butler M.D. @ButlerNash81070]

@ScottAdamsSays @ScottAdamsSays Scott call Cytodyn for the prostate compassion use trial funded by an anonymous doner. The drug LERONLIMAB turns cold tumors hot, making almost all patients responsive to immunotherapy (checkpoint inhibitors)Hot tumors are pdl1positive

https://t.co/yZIeBfjRm5

[Nashwa Butler M.D. @ButlerNash81070]

@JasonJournoDC @ScottAdamsSays Please scott call cytodyn.
Their drug leronlimab upregulates pdl1 ,turning cold tumors hot and responsive to checkpoint inhibitors.They have compassionate use Eind program funded by a private donor for prostate cancer. You have everything to gain.

[Nashwa Butler M.D. @ButlerNash81070]

@howiemandel @charliesheen https://t.co/LAtHWUqH1L paradigm shifting solid tumor treatment.

[Nashwa Butler M.D. @ButlerNash81070]

@EricLDaugh @ScottAdamsSays look into leronlimab in combo with checkpoint inhibitor.
https://t.co/LAtHWUqH1L

[Nashwa Butler M.D. @ButlerNash81070]

@ScottAdamsSays Scott look into LERONLIMAB by cytodyn. It upregulates pdl1 making checkpoint inhibitors effective.
5/5 mTNBC patients are alive now 5 years with combo leronlimab and checkpoint inhibitors

[Nashwa Butler M.D. @ButlerNash81070]

@NEWSMAX Qpa

[Nashwa Butler M.D. @ButlerNash81070]

@unusual_whales @CytoDyn @RobertKennedyJr @realDonaldTrump @DonaldJTrumpJr @elonmusk @EricTrump

[Nashwa Butler M.D. @ButlerNash81070]

@unusual_whales @CytoDyn Trump is 2020 said this is the company that will save us from COVID, HIV cure and cancer.